Details for New Drug Application (NDA): 021627
✉ Email this page to a colleague
The generic ingredient in NAMENDA is memantine hydrochloride. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the memantine hydrochloride profile page.
Summary for 021627
| Tradename: | NAMENDA |
| Applicant: | Allergan |
| Ingredient: | memantine hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021627
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;ORAL | Strength | 2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Apr 18, 2005 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 021627
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | NAMENDA | memantine hydrochloride | SOLUTION;ORAL | 021627-001 | Apr 18, 2005 | 5,614,560 | ⤷ Get Started Free |
| Allergan | NAMENDA | memantine hydrochloride | SOLUTION;ORAL | 021627-001 | Apr 18, 2005 | 5,061,703*PED | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
